Bio-Techne (TECH) Common Equity (2009 - 2026)
Bio-Techne (TECH) posted quarterly Common Equity of $2.1 billion for Q1 2026, up 3.33% year-over-year from $2.0 billion in Q1 2025, and up 3.7% quarter-over-quarter from $2.0 billion in Q4 2025.
Bio-Techne (TECH) Common Equity (2009 - 2026) Analysis & Trends
Bio-Techne's Common Equity history runs 18 years deep, the most recent figure standing at $2.1 billion for Q1 2026.
- In Q1 2026, Common Equity rose 3.33% year-over-year to $2.1 billion; the TTM figure through Mar 2026 stood at $2.1 billion (up 3.33% YoY), while the FY2025 annual figure was $1.9 billion, down 7.25% from the prior year.
- Common Equity for Q1 2026 stood at $2.1 billion, up from $2.0 billion in the prior quarter.
- The five-year high for Common Equity was $2.1 billion in Q3 2024, with the low at $1.7 billion in Q2 2022.
- The 5-year median for Common Equity is $2.0 billion (2023), against an average of $1.9 billion.
- The sharpest annual moves came in 2023 and 2025: Common Equity advanced 15.61% in 2023, then declined 8.08% in 2025.
- Bio-Techne's Common Equity stood at $1.8 billion in 2022, then climbed by 7.47% to $2.0 billion in 2023, then rose by 5.85% to $2.1 billion in 2024, then dropped by 3.25% to $2.0 billion in 2025, then rose by 3.7% to $2.1 billion in 2026.
- Business Quant data shows TECH's Common Equity at $2.1 billion in Q1 2026, $2.0 billion in Q4 2025, and $2.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Bio-Techne | 11.33 Bn | 11.12 Bn | 208.29 Mn | 2.09 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.09 Bn |
| Dec 31, 2025 | 2.01 Bn |
| Sep 30, 2025 | 1.97 Bn |
| Jun 30, 2025 | 1.92 Bn |
| Mar 31, 2025 | 2.02 Bn |
| Dec 31, 2024 | 2.08 Bn |
| Sep 30, 2024 | 2.14 Bn |
| Jun 30, 2024 | 2.07 Bn |
| Mar 31, 2024 | 2.01 Bn |
| Dec 31, 2023 | 1.96 Bn |
| Sep 30, 2023 | 2.00 Bn |
| Jun 30, 2023 | 1.97 Bn |
| Mar 31, 2023 | 1.89 Bn |
| Dec 31, 2022 | 1.83 Bn |
| Sep 30, 2022 | 1.75 Bn |
| Jun 30, 2022 | 1.70 Bn |
| Mar 31, 2022 | 1.71 Bn |
| Dec 31, 2021 | 1.70 Bn |
| Sep 30, 2021 | 1.65 Bn |
| Jun 30, 2021 | 1.57 Bn |